February 2014 | The Journal of Targeted Therapies in Cancer

March 19, 2014

The Journal of Targeted Therapies in Cancer discussed various issues regarding new and existing therapies in breast cancer with Richard Finn, MD.

March 18, 2014

Treatments for triple-negative breast cancer (TNBC) have made significantly less progress in comparison with other subtypes.

March 04, 2014

Monoclonal antibodies (mAbs) that target key “restricted” antigens in cancer cells have become an integral part of the management of multiple hematologic and solid tumor malignancies.

March 03, 2014

Eribulin mesylate has demonstrated clinical benefit as a first-line therapy for locally recurrent or metastatic HER2- negative breast cancer, according to results of a phase II, multicenter, single-arm study.

February 21, 2014

Significant developments in research and treatment for HER2-positive breast cancer have emerged over the past year. Those advances include a growing number of studies measuring the effectiveness of dual agents.

February 20, 2014

Anti-angiogenic therapy aims to disrupt blood supply to tumors and has proven clinical benefit in nonsquamous non-small cell lung cancer (NSCLC).

February 17, 2014

Previously revealed efficacy data from the BOLERO-3 study indicated slowed tumor progression in patients with trastuzumab-resistant HER2+ breast cancer, and now everolimus, trastuzumab, and vinorelbine has demonstrated a manageable safety profile.

February 14, 2014

Neoadjuvant and adjuvant therapies, administered before and after primary anticancer therapy, respectively, have been shown in numerous clinical trials to reduce recurrence and improve survival in patients with breast cancer.

February 10, 2014

Delaying resistance to hormone therapy and prolonging PFS in women with hormone receptor-positive, advanced disease have remained elusive goals in breast cancer treatment.